Management
-
Dr Sarah Howell, Ph.D. (Chief Executive Officer and Executive Director)
Sarah Howell has served as Chief Executive Officer of Arecor since 2015, leading the company through its transformation into a publicly listed, clinical-stage biotech organisation. Under her leadership, Arecor has achieved significant growth, advanced its proprietary pipeline, and strengthened strategic collaborations with global partners.
READ MORE ↓READ LESS ↑Sarah brings extensive expertise in clinical and commercial pharmaceutical product development, manufacturing, supply, and licensing across diverse therapeutic areas. Her previous senior roles include Vice President of CMC and Technical Development at BTG Plc and Director of Outsourced Manufacturing at UCB-Celltech. She holds a BSc in Chemistry from the University of Birmingham and a Ph.D. in Physical Organic Chemistry from the University of St Andrews.
She actively maintains her professional development through industry conferences, executive leadership programmes and research, ensuring she remains informed on emerging biopharma trends and governance best practices.
-
David Ellam, ACA (Chief Financial Officer and Executive Director)
David Ellam joined the Board in September 2025 as Chief Financial Officer, having worked in senior Finance roles within Biotech for 25 years. David has prior senior experience working for UK and US listed entities as well as UK and international private companies. These include BioMarin Pharmaceutical Inc., Silence Therapeutics Plc, and Juvenescence Limited.
READ MORE ↓READ LESS ↑David has contributed significantly to Board discussions, using his background in both financial and operational matters to guide the cessation of the Tetris business and the delivery of the Royalty Financing Agreement. He is a Chartered Accountant and completes the Continuing Professional Development requirements of the ICAEW. This involves undertaking a significant amount of annual training, including on ethics and technical accounting matters.
-
Jan Jezek, Ph.D., Chief Scientific Officer
Jan Jezek has been Chief Scientific Officer of Arecor since 2007 and has led R&D for the proprietary protein stabilisation technologies of the company’s Arestat® platform and their application to commercial therapeutic products. Jan is responsible for R&D activities, platform development and IP strategy.
READ MORE ↓READ LESS ↑Previously, he was a Principal Scientist at Insense Limited, a spin-out from Unilever, where he was responsible for the development of novel medical devices, taking them from concept to market.
Jan holds a joint Doctorate from the University of Bedfordshire and the University of Chemical Technology, Prague. He is a member of the Scientific Advisory Board of the Centre of Excellence in Biopharmaceuticals (University of Manchester) and is an active member of the Formulation Science & Technology Group (FSTG) at the Royal Society of Chemistry and the Biopharmaceutical Group at the Academy of Pharmaceutical Sciences (APS).
-
David Gerring, Chief Development Officer
David has 15 years’ experience in pharmaceutical product and analytical development, as well as significant regulatory and quality experience. He is Chief Development Officer at Arecor, with a wide range of responsibilities, including: scientific strategy, project management, facilities, health & safety, quality and client procurement, grant and internal product development management.
READ MORE ↓READ LESS ↑He has held senior roles at Immunocore and Emergent BioSolutions and his experience includes 5 years at UCB, whilst in a scientific and regulatory capacity. There, he focused on the development and successful licensure of Cimzia. He headed up process and analytical development at BTG, managing CMC for several recombinant products, including successful INDs and licensures.